Functional and anatomic imaging have been used almost exclusively for diagnostic purposes. Because pharmacotherapy is expected to alter organ function, functional imaging is ideally suited to assess drug effects. The application of functional imaging techniques for this purpose has recently emerged. This paper reviews application of radiopharmaceuticals and nuclear imaging techniques to the assessment of pharmacologic effects in neurology, psychiatry, cardiology, and oncology.
Anonymous. Society of Non-Invasive Imaging in Drug Developmenthttp://www.snidd.org/ Internet 2001.
2.
Raferty EB. Vasodilating beta-blockers in heart failure. Eur Heart J. 1995; 16(Suppl F):32-37.
3.
Parameshwar J, Keegan J, Mulcahy D, et al. Atenolol or nicardipine alone is as efficacious in stable angina as their combination: a double blind randomized trial. Int J Cardiol. 1993; 40(2):135-141.
4.
Jangid DR, Kasliwal RR, Bhatia ML, et al. Nuclear imaging study of nifedipine induced modulations of central hemodynamics in severe hypertension, with and without coronary artery disease. J Assoc Physicians India. 1993; 41(3):147-150.
5.
Ashmore RC, Corkadel LK, Green CL, et al. Verapamil but not nifedipine impairs left ventricular function during exercise in hypertensive patients. Am Heart J. 1990; 119(3 Pt 1):636-641.
6.
Bednarczyk EM, Furniss SM, Green JA, et al. Evaluation of the indomethacin nitroglycerin interaction using positron emission tomography. J Cardiovasc Pharmacol. 1997; 30:732-733.
7.
Gnecchi-Ruscone T, Bernard X, Pierre P, et al. Effect of naratriptan on myocardial blood flow and coronary vasodilator reserve in migraineurs. Neurology. 2000; 55(1):95-99.
8.
Gistri R, Cecchi F, Choudhury L, et al. Effect of verapamil on absolute myocardial blood flow in hypertrophic cardiomyopathy. Am J Cardiol. 1994; 74:363-368.
9.
Brunelli C, Parodi O, Sambuceti G, et al. Perfusional and metabolic effects of nisoldipine as shown by positron emission tomography after acute myocardial infarction. Am J Cardiol. 1995;75:31E-35E.
10.
Duboc D, Kahan A, Maziere B, et al. The effect of nifedipine on myocardial perfusion and metabolism in systemic sclerosis. A positron emission tomographic study. Arthritis & Rheumatism. 1991; 34(2):198-203.
11.
Gardner SF, Lazarus HM, Bednarczyk EM, et al. High-dose cyclophosphamide-induced myocardial damage during BMT: assessment by positron emission tomography. Bone Marrow Transplantation. 1993; 12:139-144.
12.
Nony P, Guastella JP, Rebattu P, et al. In vivo measurement of myocardial oxidative metabolism and blood flow does not show changes in cancer patients undergoing doxorubicin therapy. Cancer Chemo Pharmacol. 2000; 45(5):375-380.
13.
Vanovershelde JL, Wijns W, Essamri B, et al. Hemodynamic and mechanical determinants of myocardial O2 consumption in normal human heart: effects of dobutamine. Am J Physiol. 1993; 265:H1884-H1892.
14.
Pagano D, Townend JN, Parums DV, et al. Hibernating myocardium: morphological correlates of inotropic stimulation and glucose uptake. Heart. 2000; 83(4):456-461.
15.
Rosenspire KC, Haka MS, VanDort ME, et al. Synthesis and preliminary evaluation of carbon-11-meta-hydroxyephedrine: a false transmitter agent for heart neuronal imaging. J Nucl Med. 1990; 31:1328-1334.
16.
Schwaiger M, Kalff V, Rosenspire K, et al. Noninvasive evaluation of sympathetic nervous system in human heart by positron emission tomography. Circulation. 1990; 82:457-464.
17.
Syrota A.Receptor binding studies of the living heart. In: New Concepts in Cardiac Imaging. Year Book Medical Publishers, Inc.; 1988. pp. 141-166.
18.
Melon PG, Boyd CJ, McVey S, et al. Effects of active chronic cocaine use on cardiac sympathetic neuronal function assessed by carbon-11-hydroxyephedrine. J Nucl Med. 1997; 38(3):451-456.
19.
Fowler JS, Volkow ND, Logan J, et al. Alcohol intoxication does not change [11C]cocaine pharmacokinetics in human heart and brain. Synapse. 1992; 12(3):228-235.
20.
Law MP, Osman S, Pike VW, et al. Evaluation of [11C]GB67, a novel radioligand for imaging myocardial alpha 1 adenoreceptors with positron emission tomography. Eur J Nucl Med. 2000; 27(1):7-17.
21.
Dolle F, Hinnen F, Valette H, et al. Synthesis of two optically active calcium channel antagonists labeled with carbon-11 for in vivo cardiac PET imaging. Bioorganic Med Chem. 1997; 5(4):749-764.
22.
Feldman HS, Hartvig P, Wiklund L, et al. Regional distribution of 11C-labeled lidocaine, bupivicaine and ropivicaine in the heart, lungs, and skeletal muscle of pigs studied with positron emission tomography. Biopharm & Drug Disposition. 1997; 18(2):151-164.
23.
Russell CD, Young D, Billingsley JD, et al. Technical procedures for use of the new kidney agent technetium-99m MAG3. J Nucl Med Tech. 1991; 19(3):147-162.
24.
Tamaki N, Alpert NM, Rabito CA, et al. The effect of captopril on renal blood flow in renal artery stenosis assessed by positron tomography with rubidium-82. Hypertension. 1988; 11:217-222.
25.
Inaba T, Yamashita M, Kawase Y, et al. Quantitative measurement of renal plasma flow by positron emission tomography with oxygen-15 water. Tohoku J Exp Med. 1989; 159:283-289.
26.
Bernardi S, Trimble MR, Frackowiak RSJ, et al. An interictal study of partial epilepsy using positron emission tomography and the oxygen-15 inhalation technique. J Neurol, Neurosurg, Psych. 1983; 46:473-477.
27.
Chugani HT, Shewmon DA, Peacock WJ, et al. Surgical treatment of intractable neonatal-onset seizures: the role of positron emission tomography. Neurology. 1988; 38:1178-1188.
28.
Grünwald F, Menzel C, Pavics L, et al. Ictal and interictal brain SPECT imaging in epilepsy using technetium-99m-ECD. J Nucl Med. 1994; 35:1896-1901.
29.
Leiderman DB, Albert P, Balish M, et al. The dynamics of metabolic change following seizures as measured by positron emission tomography with fludeoxyglucose F18. Arch Neurol. 1994; 51:932-936.
30.
Manno EM, Sperling MR, Ding X, et al. Predictors of outcome after anterior temporal lobectomy: positron emission tomography. Neurology. 1994; 44:2331-2336.
31.
Sperling MR, Gur RC, Alavi A, et al. Subcortical metabolic alterations in partial epilepsy. Epilepsia. 1990; 31(2):145-155.
32.
Theodore WH, Dowart R, Holmes M, et al. Neuroimaging in refractory partial seizures: comparison of PET, CT, and MRI. Neurology. 1986; 36:750-759.
33.
Theodore WH, Fishbein D, Dubinsky R.Patterns of cerebral glucose metabolism in patients with partial seizures. Neurology. 1988; 38:1201-1206.
34.
Theodore WH, DrChiro G, Margolin R, et al. Barbiturates reduce human cerebral glucose metabolism. Neurology. 1986; 36:60-64.
35.
Theodore WH, Bairamian D, Newmark ME, et al. Effect of phenytoin on human cerebral glucose metabolism. J Cereb Blood Flow Metab. 1986; 6:315-320.
36.
Gaillard WD, Zeffiro T, Fazilat S, et al. Effect of valproate on cerebral metabolism and blood flow: an 18F-2-deoxyglucose and 15O water positron emission tomography study. Epilepsia. 1996; 37(6):515-521.
37.
Savic I, Blomqvist G, Halldin C, et al. Regional increases in [11C]flumazenil binding after epilepsy surgery. Acta Neurologica Scandinavica. 1998; 75(5):279-286.
38.
Olesen J, Larsen B, Lauritzen M.Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. Ann Neurol. 1981; 9:344-352.
39.
Anderson AR, Friberg L, Olsen TS, et al. Delayed hyperemia following hypoperfusion in Classic Migraine. Arch Neurol. 1988; 45:154-159.
40.
Friberg L, Olesen J, Lassen NA, et al. Cerebral oxygen extraction, oxygen consumption and regional cerebral blood flow during the aura phase of migraine. Stroke. 1994; 25:974-979.
41.
Bednarczyk EM, Remler B, Weikart C, et al. Evaluation of global cerebral blood flow, blood volume, and oxygen metabolism in patients with migraine headache. Neurology. 1998; 50:1736-1740.
42.
Bednarczyk EM, Murphy B, Galantowicz P, et al. Effect of sumatriptan on cerebral blood flow in migraineheadache. Clin Pharmacol Therap. 1997;61:141.
43.
Bednarczyk EM, Murphy B, Wack DS, et al. Nitroglycerin (GTN) model of migraine: validation of model using PET. Clin Pharmacol Therap. 1998; 63:142.
44.
Woods R, Jacoboni M, Mazziotta J.Bilateral spreading cerebral hypoperfusion during spontaneous migraine headache. NEngl J Med. 1994; 331(25):1689-1692.
45.
Fukuyama H, Ogawa M, Yamauchi Y, et al. Altered cerebral energy metabolism in Alzheimer’s disease: a PET study. J Nucl Med. 1994; 35:1-6.
46.
Azari NP, Pettigrew KD, Schapiro MB, et al. Early detection of Alzheimer’s disease: a statistical approach using positron emission tomographic data. J Cereb Blood Flow Metab. 1993; 13:438-447.
47.
Herholz K, Adams R, Kessler J, et al. Criteria for the diagnosis of Alzheimer’s disease with positron emission tomography. Dementia. 1990; 1:156-164.
48.
Salmon E, Sadzot B, Maquet P, et al. Differential diagnosis of Alzheimer’s disease with PET. J Nucl Med. 1994; 35:391-398.
49.
Ishii K, Yamaji S, Kitagaki H, et al. Regional cerebral blood flow difference between dementia with Lewy bodies and AD. Neurology. 1999; 53(2):413-416.
50.
Ishii K, Imamura T, Sasaki M, et al. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer’s disease. Neurology. 1998; 51(1):125-130.
51.
Nordberg A, Lilja A, Lundqvist H, et al. Tacrine restores cholinergic nicotinic receptors and glucose metabolism in Alzheimers patients as visualized by positron emission tomography. Neurobiologyof Aging. 1992; 13:747-758.
52.
Brunetti A, Berg G, DiChiro G, et al. Reversal of brain metabolic abnormalities following treatment of AIDS dementia complex with 3′-azio-2′,3′-dideoxythymidine (AZT, Zidovudine): A PET FDG study. J Nucl Med. 1989; 30:58-90.
53.
Tanaka Y, Minematsu K, Hirano T, et al. Effects of CDP-choline on dynamic changes in LCBF and cognitive function in demented subjects—an H215OPET study. Rinsho Shinkeigaku—Clinical Neurology. 1994; 34(9):877-881.
54.
Eberling JL, Richardson BC, Reed BR, et al. Cortical glucose metabolism in Parkinson’s disease without dementia. Neurobiology of Aging. 1993; 15(3):329-335.
55.
Holthoff VA, Vieregge P, Kessler J, et al. Discordant twins with Parkinson’s disease: positron emission tomography and early signs of impaired cognitive circuits. Ann Neurol. 1994; 36:176-182.
56.
Rougemont D, Baron JC, Collard P, et al. Local cerebral glucose utilization in treated and untreated patients with Parkinson’s disease. J Neurol Neurosurg Psych. 1984; 47(8):824-830.
57.
Jahanshahi M, Jenkins IH, Brown RG, et al. Self-initiated versus externally triggered movements I. An investigation using measurement of regional cerebral blood flow with PET and movement related potentials in normal and Parkinson’s disease subjects. Brain. 1995; 118:913-933.
58.
Montastruc JL, Celsis P, Agniel A, et al. Levodopa-induced regional cerebral blood flow changes in normal volunteer and patients with Parkinson’s disease. Lack of correlation with clinical or neuropsychological improvements. Movement Disorders. 1987; 2(4):279-289.
59.
Rinne JO, Portin RP, Ruottinen H, et al. Cognitive impairment and the brain dopaminergic system in Parkinson’s disease:[18F]fluorodopa positron emission tomographic study. Arch Neurol. 2000; 57(4):470-475.
60.
Sawle GV, Burn DJ, Morrish PK, et al. The effect of entacopne (OR-611) on brain [18F]-6-L-fluorodopa metabolism: Implications for levodopa therapy of Parkinson’s disease. Neurology. 1994; 44:1292-1297.
61.
Schwarz J, Antonini A, Tatsch K, et al. Comparison of 123I-IBZM SPECT and 11C-raclopride PET findings in patients with parkinsonism. Nuclear Medicine Communications. 1994; 15:806-813.
62.
Antonini A, Schwarz J, Oertel WH, et al. [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson’s disease. Neurology. 1994; 44:1325-1329.
63.
Antonini A, Schwarz J, Oertel WH, et al. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson’s disease: a study with positron emission tomography and [11C]raclopride. Movement Disorders. 1997; 12(1):33-38.
64.
Linazasoro G, Obeso JA, Gomez JC, et al. Modification of dopamine D2 receptor activity by Pergolide in Parkinson’s disease: an in-vivo study by PET. Clin Neuro Pharmacol. 1999; 22(5):277-280.
65.
Volkow ND, Wang GJ, Fowler JS, et al. Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D(2) receptors. J Pharmacol Exp Therap. 1999; 291(1):409-415.
66.
Volkow ND, Wang GJ, Fowler JS, et al. Methylphenidate and cocaine have a similar in vivo potency to block dopamine transporters in the human brain. Life Sciences. 1999; 65(1):PL7-PL12.
67.
Ghatan PH, Ingvar M, Eriksson L, et al. Cerebral effects of nicotine during cognition in smokers and non-smokers. Psychopharmacology. 1998; 136:179-189.
68.
Volkow ND, Hitzemann R, Wolf AP, et al. Acute effects of ethanol on regional brain glucose metabolism and transport. Psychiatry Research. 1990; 35:39-48.
69.
Volkow ND, Mullani N, Gould L, et al. Effects of acute alcohol intoxication on cerebral blood flow measured with PET. !Psychiatry Research. 1988; 24:201-209.
70.
Cameron OG, Modell JG, Hariharan M.Caffeine and human cerebral blood flow: a positron emission tomography study. Life Sciences. 1990; 47:1141-1146.
71.
Ernst M, Zametkin AJ, Matochik JA, et al. Effects of intravenous dextroamphetamine on brain metabolism in adults with attention deficit hyperactivity disorder (ADHD). Preliminary findings. Psychopharmacology Bulletin. 1994; 30(2):219-225.
72.
Matochik JA, Liebenauer LL, King AC, et al. Cerebral glucose metabolism in adults with attention deficit hyperactivity disorder after chronic stimulant treatment. Am J Psychiatry. 1994; 151(5):658-664.
73.
Volkow ND, Wang GJ, Fowler JS, et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry. 1998; 155(10):1325-1331.
74.
Wu JS, Buchsbaum MS, Hershey TG, et al. PET in generalized anxiety disorder. Biol Psychiatry. 1991; 29:1181-1199.
75.
Buchsbaum MS, Wu J, Haier R, et al. Positron emission tomography assessment of effects of benzodiazepines on regional glucose metabolic rate in patients with anxiety disorder. Life Sciences. 1987; 40:2393-2400.
76.
Reiman EM, Raichle ME, Robins E, et al. Neuroanatomical correlates of a lactate-induced anxiety attack. Arch Gen Psychiat. 1989; 46:493-500.
77.
Benkelfat C, Bradwejn J, Meyer E, et al. Functional neuroanatomy of CCK4-induced anxiety in normal healthy volunteers. Am J Psychiatry. 1995; 152:1180-1184.
78.
Wolkin A, Angrist B, Wolf A, et al. Effects of amphetamines on local cerebral metabolism in normal and schizophrenic subjects as determined by positron emission tomography. Psychopharmacology. 1987; 92:241-246.
79.
Wolkin A, Jaeger J, Brodie JD, et al. Persistence of cerebral metabolic abnormalities in chronic schizophrenia as determined by positron emission tomography. Am J Psychiatry. 1985; 142:564-571.
80.
Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000; 157(4):514-520.
81.
Delbeke D.Oncologic applications of FDG PET imaging. J Nucl Med. 1999; 40:1706-1715.
82.
Dehdashti F, Mortimer JE, Siegel BA, et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med. 1995; 36:1766-1774.
83.
Hustinx R, Eck SL, Alavi A.Potential applications of PET imaging in developing novel cancer therapies. J Nucl Med. 1999; 40:995-1002.
84.
Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999; 35(13):1773-1782.
85.
Ichiya Y, Kuwabara Y, Otsuka M, et al. Assessment of response to cancer therapy using Fluorine-18-fluorodeoxyglucose and positron emission tomography. J Nucl Med. 1991; 32:1655-1660.
86.
Hoekstra CJ, Paglianti I, Hoekstra OS, et al. Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: an overview of different analytical methods. Eur J Nucl Med. 2000; 27:731-743.
87.
Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med. 1996; 23(10):1409-1415.
